LAVA Therapeutics NV
NASDAQ:LVTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (1), the stock would be worth $9.97 (473% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | $1.74 |
0%
|
| 3-Year Average | 1 | $9.97 |
+473%
|
| 5-Year Average | 0.6 | $5.58 |
+221%
|
| Industry Average | 52.8 | $511.53 |
+29 298%
|
| Country Average | 15.6 | $151.39 |
+8 601%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$-10.4m
|
/ |
Apr 2025
$-57.9m
|
= |
|
|
$-10.4m
|
/ |
Dec 2025
$-27.8m
|
= |
|
|
$-10.4m
|
/ |
Dec 2026
$-34.4m
|
= |
|
|
$-10.4m
|
/ |
Dec 2027
$-34.5m
|
= |
|
|
$-10.4m
|
/ |
Dec 2028
$-20.1m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| NL |
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
45.8m USD | 0.2 | -0.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.1B USD | 19.9 | 86 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.7B USD | 14.2 | 24.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.6B USD | 15.3 | 19.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.5B USD | 22.1 | 28.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 14.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 43.5 | 39.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.3B AUD | 13.6 | 32.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 12.2 |
| Median | 15.6 |
| 70th Percentile | 20.9 |
| Max | 706 |
Other Multiples
LAVA Therapeutics NV
Glance View
LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
